Jefferies Group LLC set a $5.00 target price on Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in a research note released on Friday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently issued reports on XENE. Canaccord Genuity reaffirmed a buy rating and set a $5.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, June 27th. Zacks Investment Research raised Xenon Pharmaceuticals from a sell rating to a hold rating in a research report on Saturday, July 1st. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Xenon Pharmaceuticals currently has a consensus rating of Buy and an average target price of $11.88.

Xenon Pharmaceuticals (NASDAQ XENE) opened at 3.05 on Friday. The firm’s market capitalization is $54.89 million. The firm’s 50-day moving average is $3.46 and its 200-day moving average is $5.32. Xenon Pharmaceuticals has a 12 month low of $2.85 and a 12 month high of $9.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by $0.03. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.38 million. Xenon Pharmaceuticals had a negative return on equity of 47.53% and a negative net margin of 3,489.63%. On average, equities research analysts expect that Xenon Pharmaceuticals will post ($0.76) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/08/08/xenon-pharmaceuticals-inc-nasdaqxene-given-a-5-00-price-target-at-jefferies-group-llc.html.

In other Xenon Pharmaceuticals news, insider Value Fund L. P. Biotechnology acquired 358,698 shares of Xenon Pharmaceuticals stock in a transaction dated Wednesday, June 7th. The stock was bought at an average cost of $3.81 per share, with a total value of $1,366,639.38. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Value Fund L. P. Biotechnology acquired 20,411 shares of Xenon Pharmaceuticals stock in a transaction dated Thursday, June 22nd. The stock was acquired at an average cost of $4.00 per share, with a total value of $81,644.00. The disclosure for this purchase can be found here. Insiders bought 490,978 shares of company stock valued at $1,891,534 over the last three months. 9.40% of the stock is owned by company insiders.

Several large investors have recently bought and sold shares of the stock. Endurant Capital Management LP acquired a new stake in Xenon Pharmaceuticals during the first quarter valued at $1,363,000. Sabby Management LLC acquired a new stake in Xenon Pharmaceuticals during the first quarter valued at $1,186,000. Renaissance Technologies LLC boosted its stake in Xenon Pharmaceuticals by 90.1% in the first quarter. Renaissance Technologies LLC now owns 217,090 shares of the biopharmaceutical company’s stock valued at $868,000 after buying an additional 102,890 shares in the last quarter. K2 Principal Fund L.P. boosted its stake in Xenon Pharmaceuticals by 104.4% in the first quarter. K2 Principal Fund L.P. now owns 116,975 shares of the biopharmaceutical company’s stock valued at $468,000 after buying an additional 59,747 shares in the last quarter. Finally, KCG Holdings Inc. acquired a new stake in Xenon Pharmaceuticals during the first quarter valued at $122,000. 56.01% of the stock is owned by institutional investors.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).

Analyst Recommendations for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.